down arrow

Lyell Immunopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US55083R1041
USD
25.46
4.65 (22.35%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

21.3925.59

52 Week

7.6525.59
Valuation
Technical
Day's Volume

CASH

93.53 k

Shareholding (Jun 2025)

FII

22.36%

Held by 61 FIIs

DII

21.34%

Held by 14 DIIs

Promoter

43.48%

How big is Lyell Immunopharma, Inc.?

22-Jun-2025

As of Jun 18, Lyell Immunopharma, Inc. has a market capitalization of 143.64 million, with net sales of 0.06 million and a net profit of -334.53 million over the latest four quarters. Shareholder's funds are 382.82 million, and total assets are 490.86 million.

Market Cap: As of Jun 18, Lyell Immunopharma, Inc. has a market capitalization of 143.64 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.06 million and a net profit of -334.53 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 382.82 million, while total assets were reported at 490.86 million.

Read More

What does Lyell Immunopharma, Inc. do?

22-Jun-2025

Lyell Immunopharma, Inc. is a micro-cap biotechnology company with no recent net sales and a net loss of $52 million as of March 2025. It has a market cap of $143.64 million and key metrics indicating significant financial challenges, including a negative return on equity and no dividend yield.

Overview: <BR>Lyell Immunopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 143.64 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.87 <BR>Return on Equity: -56.34% <BR>Price to Book: 0.43<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Lyell Immunopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of February 29, 2024, Lyell Immunopharma, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a year-to-date decline of 29.77%, significantly underperforming compared to the S&P 500's 2.44% gain.

As of 29 February 2024, the valuation grade for Lyell Immunopharma, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company's current valuation suggests it is overvalued, particularly given its negative financial metrics. Key ratios include a price-to-book value of 0.56 and an EV to EBITDA of 0.50, which, while low, reflect the company's struggles rather than an attractive investment opportunity.<BR><BR>In comparison to its peers, Lyell Immunopharma's valuation metrics are concerning. For instance, Scholar Rock Holding Corp. has a more negative EV to EBITDA of -9.8457, while Janux Therapeutics, Inc. shows a risky valuation with an EV to EBITDA of -3.1688. Furthermore, Lyell's return performance has been dismal, with a year-to-date decline of 29.77%, contrasting sharply with the S&P 500's 2.44% gain. Overall, the combination of negative ratios and poor market performance reinforces the view that Lyell Immunopharma is currently overvalued.

Read More

Is Lyell Immunopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Lyell Immunopharma, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly over the past year and three years.

As of 1 August 2025, the technical trend for Lyell Immunopharma, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish and bullish, respectively. However, the monthly indicators show a bearish trend in both the Bollinger Bands and KST. Overall, the mixed signals suggest a mildly bearish outlook. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -53.19% compared to the S&P 500's 17.14%, and a 3-year return of -91.21% versus 70.41% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 250 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.93

stock-summary
Return on Equity

-61.82%

stock-summary
Price to Book

0.84

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
122.75%
0%
122.75%
6 Months
218.65%
0%
218.65%
1 Year
35.63%
0%
35.63%
2 Years
-33.35%
0%
-33.35%
3 Years
531.76%
0%
531.76%
4 Years
-85.68%
0%
-85.68%
5 Years
0%
0%
0.0%

Lyell Immunopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Lyell Immunopharma, Inc. technically bullish or bearish?

As of 1 August 2025, the technical trend for Lyell Immunopharma, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish and bullish, respectively. However, the monthly indicators show a bearish trend in both the Bollinger Bands and KST. Overall, the mixed signals suggest a mildly bearish outlook. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -53.19% compared to the S&P 500's 17.14%, and a 3-year return of -91.21% versus 70.41% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-71.63%
EBIT Growth (5y)
2.04%
EBIT to Interest (avg)
-218.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
59.37%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.56
EV to EBIT
0.46
EV to EBITDA
0.50
EV to Capital Employed
-2.39
EV to Sales
-103.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-56.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 41 Schemes (12.82%)

Foreign Institutions

Held by 61 Foreign Institutions (22.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 18.20% vs 72.80% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.50",
          "val2": "-54.00",
          "chgp": "23.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "-1.30",
          "chgp": "-84.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.70",
          "val2": "-52.20",
          "chgp": "18.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,579,375.00%",
          "val2": "-8,212,285.70%",
          "chgp": "2,63,291.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -99.88% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -46.21% vs -28.13% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-204.30",
          "val2": "-230.50",
          "chgp": "11.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-156.10",
          "val2": "-14.80",
          "chgp": "-954.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-343.00",
          "val2": "-234.60",
          "chgp": "-46.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,670,344.30%",
          "val2": "-1,928,676.90%",
          "chgp": "-1,74,166.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-41.50
-54.00
23.15%
Interest
0.00
0.00
Exceptional Items
-2.40
-1.30
-84.62%
Consolidate Net Profit
-42.70
-52.20
18.20%
Operating Profit Margin (Excl OI)
-5,579,375.00%
-8,212,285.70%
2,63,291.07%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 18.20% vs 72.80% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-204.30
-230.50
11.37%
Interest
0.00
0.00
Exceptional Items
-156.10
-14.80
-954.73%
Consolidate Net Profit
-343.00
-234.60
-46.21%
Operating Profit Margin (Excl OI)
-3,670,344.30%
-1,928,676.90%
-1,74,166.74%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -99.88% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -46.21% vs -28.13% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lyell Immunopharma, Inc. stock-summary
stock-summary
Lyell Immunopharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."